Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 19827992)

1.

Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.

Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

J Med Econ. 2009;12(4):348-55. doi: 10.3111/13696990903378680.

PMID:
19827992
2.

Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.

Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Curr Med Res Opin. 2009 Nov;25(11):2703-9. doi: 10.1185/03007990903307755.

PMID:
19775195
3.

Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.

Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A; Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP).

Pediatrics. 2006 May;117(5):e817-20.

PMID:
16651285
4.

Gastroesophageal reflux disease: exaggerations, evidence and clinical practice.

Ferreira CT, Carvalho Ed, Sdepanian VL, Morais MB, Vieira MC, Silva LR.

J Pediatr (Rio J). 2014 Mar-Apr;90(2):105-18. doi: 10.1016/j.jped.2013.05.009. Epub 2013 Oct 30. Review.

5.

Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.

Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY.

Eur J Gastroenterol Hepatol. 2013 Jan;25(1):15-21. doi: 10.1097/MEG.0b013e3283595086.

PMID:
23022985
6.

Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.

Kim KM, Cho YK, Bae SJ, Kim DS, Shim KN, Kim JH, Jung SW, Kim N.

J Gastroenterol Hepatol. 2012 Apr;27(4):741-5. doi: 10.1111/j.1440-1746.2011.06921.x.

PMID:
21916988
7.

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.

Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.

Value Health. 2009 Jan-Feb;12(1):34-9. doi: 10.1111/j.1524-4733.2008.00399.x. Epub 2008 Jul 15.

PMID:
19895371
8.

Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.

van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA.

Pediatrics. 2011 May;127(5):925-35. doi: 10.1542/peds.2010-2719. Epub 2011 Apr 4. Review.

9.

The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.

El-Serag HB, Fitzgerald S, Richardson P.

Am J Gastroenterol. 2009 Sep;104(9):2161-7. doi: 10.1038/ajg.2009.312. Epub 2009 Jun 30.

PMID:
19568229
10.

Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.

Hall J, Dodd S, Durkin M, Sloan S.

Manag Care. 2002 Jul;11(7 Suppl):14-8.

11.

Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease.

Gawron AJ, Pandolfino JE, Miskevics S, Lavela SL.

J Gen Intern Med. 2013 Jul;28(7):930-7. doi: 10.1007/s11606-013-2345-0.

12.

Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease.

Ruigómez A, Hungin AP, Lundborg P, Johansson S, Wallander MA, García Rodríguez LA.

Eur J Gastroenterol Hepatol. 2011 Mar;23(3):232-7. doi: 10.1097/MEG.0b013e328343b06e.

PMID:
21258240
13.

Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.

Ruigómez A, Johansson S, Wernersson B, Fernández Cantero O, García Rodríguez LA.

Scand J Gastroenterol. 2012 Jul;47(7):751-61. doi: 10.3109/00365521.2012.679682. Epub 2012 Apr 23.

PMID:
22519917
14.

How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?

de Bortoli N, Nacci A, Savarino E, Martinucci I, Bellini M, Fattori B, Ceccarelli L, Costa F, Mumolo MG, Ricchiuti A, Savarino V, Berrettini S, Marchi S.

World J Gastroenterol. 2012 Aug 28;18(32):4363-70. doi: 10.3748/wjg.v18.i32.4363.

15.

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.

Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G.

Am J Gastroenterol. 2000 Feb;95(2):395-407.

PMID:
10685741
16.

Marked increase in proton pump inhibitors use in Australia.

Hollingworth S, Duncan EL, Martin JH.

Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1019-24. doi: 10.1002/pds.1969.

PMID:
20623646
17.

Proton pump inhibitor utilization patterns in infants.

Barron JJ, Tan H, Spalding J, Bakst AW, Singer J.

J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):421-7.

PMID:
18030207
18.

Development of a refractory gastro-oesophageal reflux score using an administrative claims database.

Gerson LB, Bonafede M, Princic N, Gregory C, Farr A, Balu S.

Aliment Pharmacol Ther. 2011 Sep;34(5):555-67. doi: 10.1111/j.1365-2036.2011.04755.x. Epub 2011 Jun 30.

PMID:
21714794
19.

Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database, [1997-2009].

De Bruyne P, Christiaens T, Vander Stichele R, Van Winckel M.

J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):220-5. doi: 10.1097/MPG.0b013e3182a3b04e.

PMID:
24464148
20.

The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts.

Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B.

Clin Drug Investig. 2010;30(3):167-78. doi: 10.2165/11531670-000000000-00000.

PMID:
20155989
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk